Healthcare shares are flat to lower in pre-market, while shares
in Pluristem Therapeutics (
), which is developing placenta-based cell therapies, are up more
than 6% pre-market. PSTI said it has been granted a patent by the
U.S. Patent and Trademark Office covering methods to treat
peripheral artery disease with placental-derived adherent stromal
The treatment for PAD is one of PSTI's primary drug development
areas. Based on priority date, the expected expiration date of this
patent is at least until 2028.
And, Merck & Co. (
) and AstraZeneca plc (
) entered into a licensing agreement for Merck's oral small
molecule inhibitor of WEE1 kinase.
Under the terms of the agreement, AstraZeneca will pay Merck a
$50 million upfront fee. In addition Merck will be eligible to
receive future payments tied to development and regulatory
milestones, plus sales-related payments and tiered royalties.
AstraZeneca will be responsible for all future clinical
development, manufacturing and marketing.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.